A study profiling antigens presented on immune and tumor cells in co-culture points to new strategies for attacking a treatment-resistant and deadly brain cancer.
By examining antigen architectures, MIT researchers built a therapeutic cancer vaccine that may improve tumor response to immune checkpoint blockade treatments.
Researchers decipher when and why immune cells fail to respond to immunotherapy, and suggest that T cells need a different kind of prodding in order to re-engage the immune response.